FDA Approves New FcRN Blocker to Treat Generalized Myasthenia Gravis
Johnson & Johnson has received U.S. Food and Drug Administration (FDA) approval for IMAAVY (nipocalimab-aahu), a human FcRn-blocking monoclonal antibody, for the treatment of generalized myasthenia gravis
Uplizna Approved to Treat IgG4-Related Disease
Amgen’s UPLIZNA has been approved by the U.S. Food and Drug Administration as the first and only treatment for adults living with Immunoglobulin G4-related disease.
Grifols Receives $21M to Study Parkinson’s Plasma Samples
Grifols has received $21 million from the Michael J. Fox Foundation to fund a pilot study analyzing the company’s repository of longitudinal Parkinson’s disease (PD) plasma samples in hopes of developing an early-warning system for the emergence of PD.
Common Virus May Cause a Type of Alzheimer’s
Researchers have discovered a link between a chronic gut infection caused by cytomegalovirus and the development of Alzheimer’s disease in some people.
Blood Test Can Predict How Long Vaccine Immunity Will Last
A study led by researchers at Stanford Medicine has shown that variation in vaccine durability can, in part, be attributed to a type of blood cell called megakaryocytes, typically implicated in blood clotting.
CMS Releases Proposed 2026 Payment Policy Updates for MA and Part D Programs
The Centers for Medicare and Medicaid Services released the 2026 Advance Notice for the Medicare Advantage and the Medicare Part D Prescription Drug Programs that would update payment policies for these programs.
Triglyceride Drug Approved to Treat Adults with FCS
Tryngolza (olezarsen) has been approved by the U.S. Food and Drug Administration to be used with diet to reduce triglycerides (TG) in adults with familial chylomicronemia syndrome.
Coupling HA Molecules from Various Flu Strains Could Make Vaccines More Effective
Results from a recent study suggest coupling HA molecules from various flu strains could make flu vaccines more effective.
FDA Approves Chikungunya Vaccine
The U.S. Food and Drug Administration (FDA) has approved VIMKUNYA (chikungunya vaccine, recombinant) for injection, the first virus-like particle (VLP) single-dose chikungunya vaccine in the U.S. for persons 12 years of age and older.
HHS Announces 15 Additional Drugs for Price Negotiations
The Centers for Medicare and Medicaid Services (CMS) has announced the selection of 15 additional drugs covered under Medicare Part D for price negotiations.
